Introduction
============

Lymphoma may arise from a nodal or extra-nodal origin, and the number of patients with extra-nodal non-Hodgkin\'s lymphoma (NHL) is rapidly increasing ([@b1-ol-0-0-8803],[@b2-ol-0-0-8803]). The exact designation of primary extra-nodal NHL (PE-NHL) is controversial, particularly when both nodal and extra-nodal sites are involved; a number of studies have described PE-NHL as presenting only in extra-nodal sites, with no visible lymphadenopathy on imaging ([@b3-ol-0-0-8803],[@b4-ol-0-0-8803]), while others have used a broader definition, in which extra-nodal disease with regional or distant involved lymph nodes is included ([@b1-ol-0-0-8803],[@b5-ol-0-0-8803]). In the present study, the former definition was selected. The incidence of PE-NHL varies between countries, accounting for 15--48% of NHL cases. The most common pathological type of PE-NHL is diffuse large B-cell lymphoma (DLBCL), representing 71--81.3% of cases ([@b6-ol-0-0-8803],[@b7-ol-0-0-8803]). Although lymphomas may involve almost all extra-nodal organs, different organs are involved at different frequencies. Primary extra-nodal DLBCLs (PE-DLBCLs) are common in the gastrointestinal (GI) tract, and are relatively uncommon in the central nervous system (CNS), thyroid, breast, female genital system (FGS), testis, skin, adrenal gland, pancreas, bone or other sites ([@b6-ol-0-0-8803],[@b8-ol-0-0-8803],[@b9-ol-0-0-8803]).

CNS relapse is nearly always fatal, and the overall risk of CNS relapse of patients with DLBCL is \~5% ([@b10-ol-0-0-8803]). However, the incidence is much higher in patients when breast, adrenal gland or testicular sites are involved.

The diversity of clinical presentations suggests that PE-DLBCLs are distinct entities, and efforts regarding the risk factors and prevention methods for CNS recurrence are inconclusive. Thus, the present study retrospectively analyzed the clinical features, response to therapy, long-term outcomes and CNS relapse of patients with PE-DLBCL at the Department of Hematology (Peking Union Medical College Hospital, Beijing, China).

Patients and methods
====================

### Patients

A total of 677 patients (median age 58 years, age range 12--78 years; male to female ratio 71:10) diagnosed with DLBCL and treated at Peking Union Medical College Hospital between December 2003 and December 2013, and 141 patients diagnosed with PE-NHL were evaluated. The median age was 58 (range, 12--78), and the sex ratio of male and female was 71:70. All biopsies were classified according to the World Health Organization classification system ([@b11-ol-0-0-8803]) and were analyzed by immunohistochemistry. When lymphomas were contiguous with neighboring organs, the site with the largest area of involvement was defined as the dominant site. The Ann Arbor stage for PE-NHL involving bilateral paired organs or diffuse lesions of an organ remains a source of contention, but in the present study, these situations were considered as stage IV. Patients presenting with either systemic disease, primary nodal NHL with secondary extra-nodal involvement, infection with human immunodeficiency virus, hepatitis C or B, or recurrent lymphoma following previous treatment were excluded from the study.

Measurements of complete blood count and biochemical parameters, including serum lactate dehydrogenase (LDH), serum total protein, serum albumin, creatinine, serum urea, uric acid, liver enzymes and bilirubin, and bone marrow aspiration and trephine biopsy, whole body computed tomography scan, fluorodeoxyglucose positron emission tomography (FDG-PET) and magnetic resonance imaging (MRI) of the brain were performed prior to and following treatment. Patients were staged and evaluated according to the Ann Arbor classification ([@b12-ol-0-0-8803]) and the International Prognostic Index (IPI) score ([@b13-ol-0-0-8803]). Patients with primary gastrointestinal DLBCL were evaluated by Lugano classification ([@b14-ol-0-0-8803]).

All procedures were performed in accordance with the ethical standards of the responsible Ethics Committee of Peking Union Medical College Hospital (Beijing, China) on human experimentation (institutional and national) and with the Declaration of Helsinki (1975), as revised in 2000. Written informed consent was obtained from all patients included in the study.

### Treatment and response

First-line therapy for patients with primary CNS-DLBCL (PCNS-DLBCL) was high-dose methotrexate (HD-MTX)-based combined chemotherapy (CT; 3 g/m^2^ over 4 h rapid infusion time; the cycle length of HD-MTX transfusion was 28 days and the number of cycles was 6--8.) and 14 patients received radiotherapy (RT; 40--50 Gy) after CT. The first-line treatment for the remaining PE-DLBCL patients was CHOP (cyclophosphamide 750 mg/m^2^ iv d1, doxorubicin 50 mg/m^2^ iv d1, vindesine 1.4 mg/m^2^ iv d1, prednisone 100 mg, po d1-5) or CHOP-like regimen combined with rituximab (R-CHOP. rituximab 375 mg/m^2^ d1). The regimen was given every 21 days for 6--8 cycles. However, 49 patients selected treatment without rituximab due to its high cost. A total of 32 patients underwent surgery for definitive diagnosis and 10 patients for the management of complications.

The National Comprehensive Cancer Network (NCCN) ([@b15-ol-0-0-8803]) guidelines divide patients into low (score, 0--1), moderate (score, 2--3) and high-risk (score, 4--6) CNS relapse groups based on the IPI (5 scores) and kidney or adrenal involvement (1 score). Due to the retrospective nature of the present study, scoring procedures were not standardized and not all variables were available for each patient. In 2012, our center began administering intravenous injections of HD-MTX for the prevention of CNS recurrence. A total of 68 patients with a moderate or high risk of CNS relapse received prophylaxis, including 36 patients that only received intrathecal injection, 19 patients that only received the intravenous injection of HD-MTX (1 g/m^2^ for 4 cycles) and 13 patients that received both.

The response to treatment was assessed, following the completion of initial therapy, according to the International Working Group criteria ([@b16-ol-0-0-8803]) as complete remission (CR), partial remission (PR), stable disease (SD) or progressive disease (PD).

### Follow-up

Patients were followed up every 3 months for the first 3 years after treatment and every 6 months thereafter. Routine examinations were performed during the follow-up period, including physical examination, laboratory tests, echocardiography, and a whole-body computed tomography scan or FDG-PET. Lumbar puncture head MRIs were performed on those with primary CNS involvement or the clinical symptoms of CNS relapse. The final follow-up date was November 31, 2016. Among all 141 patients, 16 were lost to follow-up.

### Statistical analysis

Overall survival (OS) was calculated from the date of diagnosis to the date of last follow-up or mortality from any cause. Progression-free survival (PFS) was evaluated from the date of diagnosis to the date of disease progression or relapse. Statistical analysis was performed using SPSS 19.0 software (IBM Corp., Armonk, NY, USA). The Kaplan-Meier method and the log-rank test were used for univariate analysis and the generation of survival curves. All factors with P-values \<0.10 were included in the multivariate analysis using the Cox proportional hazards model. Differences were evaluated using a two-tailed test; P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Clinical characteristics

Patients with PE-DLBCL accounted for 20.8% of all the patients with NHL during the study period. The characteristics of the patients at diagnosis are summarized in [Table I](#tI-ol-0-0-8803){ref-type="table"}. The presence of B symptoms was less common in patients with primary CNS, breast, thyroid gland or FGS involvement than it was for other sites. The majority of patients were classified as clinical stage I--II (87; 61.7%), whereas the number of patients at stage III/IV was highest for patients with primary adrenal gland (12/15; 80.0%) and bone (6/7; 85.7%) involvement. The overall distribution of patients with PE-DLBCL is presented in [Table II](#tII-ol-0-0-8803){ref-type="table"}.

### Response to treatment and survival

The median OS and PFS times of patients with PE-DLBCL were 28 months (range, 1--116 months) and 17 months (range, 1--108 months), respectively. The OS and PFS rates differed between patients with the primary involvement of different sites ([Table III](#tIII-ol-0-0-8803){ref-type="table"}). Although the prognosis was improved for patients with primary thyroid DLBCL (PT-DLBCL), compared with those primary adrenal gland DLBCL (PA-DLBCL), the difference was not statistically significant (P=0.178; [Fig. 1](#f1-ol-0-0-8803){ref-type="fig"}). The median OS times of patients with primary GI tract, CNS, adrenal gland, breast, FGS, thyroid and bone involvement were 36.5 months (range, 1--108), 29 months (range, 1--112), 14 months (range, 2--94), 25 months (range, 3--79), 20 months (range, 3--60), 22 months (range, 16--50) and 18.5 months (range, 15--37), respectively, and the PFS times were 25.5 months (range, 1--108), 24 months (range, 1--85), 10 months (range, 1--50), 20 months (range, 3--79), 11 months (range, 3--84), 22 months (range, 1--50) and 12.5 months (range, 9--20), respectively.

A total of 59 patients with PE-DLBCL achieved CR (47.5%) and 15 achieved PR (12.1%), resulting in a total response rate (RR) of 59.6%. The RR for patients with PT-DLBCL was 100%, while that of those with primary bone, breast, FGS, CNS, GI tract, and adrenal gland involvement was 75, 64.3, 63.6, 58.1, 57.1 and 33.3%, respectively. Patients treated with rituximab exhibited a better RR than those not treated with rituximab (68.2 vs. 34.1%).

### Prognostic factors

The survival rate was not significantly influenced by age, sex, Eastern Cooperative Oncology Group performance status ([@b17-ol-0-0-8803]), primary site or bone marrow involvement. Univariate analysis demonstrated that elevated serum LDH, B symptoms, Ann Arbor stage, inclusion of rituximab, CR following first-line therapy and IPI significantly affected survival ([Fig. 2](#f2-ol-0-0-8803){ref-type="fig"}). In the multivariate analysis, IPI ≤2, CR following first-line treatment and combination with rituximab were independent predictive factors for OS in patients with PE-DLBCL; the latter two were also significantly associated with PFS ([Table III](#tIII-ol-0-0-8803){ref-type="table"}). Patients could be divided into four groups with different prognoses on the basis of IPI ([Fig. 3](#f3-ol-0-0-8803){ref-type="fig"}).

Of the patients with primary GI DLBCL (PGI-DLBCL), 23 received surgery combined with CT, 20 of which were Lugano stage I--IIE and 8 (40.0%) of which succumbed to the primary disease during follow-up. A total of 8 patients with primary FGS-DLBCL (PFGS-DLBCL) and 5 patients with primary breast DLBCL (PB-DLBCL) underwent surgery. However, no statistically significant differences were observed in the 3-year OS and PFS rates between patients who had and had not undergone surgery ([Table IV](#tIV-ol-0-0-8803){ref-type="table"}).

A total of 22 patients with PCNS-DLBCL received CT alone, and 9 were treated with CT followed by RT. The 3-year OS rates of the two groups were 57.8 and 66.7% respectively, and the 3-year PFS rates were 56.8 and 62.5% respectively, but no significant differences were observed between the two groups (P=0.592 vs. P=0.703).

### Analysis of CNS relapse

A higher rate of CNS relapse was observed in patients with primary FGS (6/11, 54.5%) and adrenal gland (3/15, 20.0%) involvement compared with other sites, and the difference was statistically significant ([Table V](#tV-ol-0-0-8803){ref-type="table"}). A significant trend towards a prolonged time to CNS relapse following intravenous rituximab treatment was observed (P=0.003; [Fig. 4](#f4-ol-0-0-8803){ref-type="fig"}), but neither intravenous HD-MTX nor intrathecal injection reduced the incidence of CNS recurrence (P=0.689 and P=0.876, respectively).

Discussion
==========

PE-DLBCL is a heterogeneous disease with various clinical manifestations and molecular alterations at different anatomical sites. The majority of patients with primary nodal DLBCL are classified as clinical stage III--IV ([@b18-ol-0-0-8803],[@b19-ol-0-0-8803]), whereas only 38.3% of patients in the present study exhibited stage III--IV disease, a difference that may be the consequence of the variation in the definition of primary extra-nodal involvement, or differences in staging criteria. When lymphomas presented at extra-nodal organs with distant lymph node, spleen or thymus involvement, they were categorized as primary nodal NHL, leading to more patients being classified as stage I--II.

For PE-DLBCL patients with localized lesions, neither surgery nor radiotherapy alone is preferred, and the choice of treatment strategies should be adjusted according to the stratification of anatomic location and disease stage. Several studies have demonstrated improved OS in the groups of patients with PGI-DLBCL who underwent surgery combined with CT, particularly in those with early disease stages ([@b20-ol-0-0-8803]--[@b23-ol-0-0-8803]). However, certain centers suggest that patients with stage I--II PGFS-DLBCL should be treated with systemic CT and localized RT or surgery to optimize chances of remission ([@b24-ol-0-0-8803]--[@b26-ol-0-0-8803]). In previous studies, mastectomy was reported to be non-beneficial for patients with PB-DLBCL ([@b27-ol-0-0-8803]--[@b29-ol-0-0-8803]) or PT-DLBCL ([@b30-ol-0-0-8803]--[@b32-ol-0-0-8803]), and the International Extra-Nodal Lymphoma Study Group (IELSG) revealed that radical mastectomy is an adverse factor for cause-specific survival in multivariate analysis ([@b29-ol-0-0-8803]). In the present study, mastectomy combined with CT was not associated with improved outcomes in patients with primary GI tract, FGS, breast or thyroid involvement. Surgery was performed on 15 patients with PGI-DLBCL who required pathological diagnosis, and 8 who were experiencing bleeding, perforation or other acute complications, delaying the commencement of CT, with a detrimental outcome. Limited by the small number of patients with primary breast, FGS or thyroid involvement, and due to the study\'s retrospective nature and lack of randomized comparisons, the present study has not reliably assessed the effect of surgery on survival.

HD-MTX is considered to be the most effective agent for treating PCNS-DLBCL ([@b33-ol-0-0-8803]), and the addition of high-dose cytarabine (HD-Ara-C) has been demonstrated to significantly improve the RR and failure-free survival ([@b34-ol-0-0-8803],[@b35-ol-0-0-8803]). The efficacy of adding of whole brain RT (WBRT) to HD-MTX-based CT as consolidative therapy is debatable. Doses of 30--36 Gy to the whole brain are currently used ([@b36-ol-0-0-8803]--[@b39-ol-0-0-8803]), but certain studies do not report a clear benefit of WBRT in prolonging OS ([@b40-ol-0-0-8803]--[@b42-ol-0-0-8803]). In the present study, WBRT with CT improved the 3-year OS rate, but the difference was not statistically significant, potentially due to the fact that 5 of the 9 patients who underwent CT combined with WBRT selected RT as salvage therapy, and 3 patients began RT prior to achieving CR. Nonetheless, there is a general agreement that WBRT is associated with delayed treatment-associated neurotoxicity and that it may hinder the benefits of disease control ([@b40-ol-0-0-8803]--[@b42-ol-0-0-8803]). Recently, Ibrutinib ([@b43-ol-0-0-8803]) and Nivolumab ([@b44-ol-0-0-8803]) were reported to be active in relapsed/refractory PCNS lymphoma, as previous studies have demonstrated that PCNS-DLBCL is characterized by a high expression of myeloid differentiation primary response 88 (MYD88) ([@b45-ol-0-0-8803]--[@b47-ol-0-0-8803]), and programmed death (PD)-1/PD-ligand 1 is immunohistochemically and genetically detectable ([@b48-ol-0-0-8803],[@b49-ol-0-0-8803]). These studies outline potential future treatments for PCNS-DLBCL.

In the present study, three main prognostic factors were identified that influenced survival-rituximab, IPI and achieving CR following first-line therapy. The wide application of rituximab, R-CHOP or R-CHOP-like regimens have achieved significant therapeutic effects in DLBCL ([@b50-ol-0-0-8803]). At present, systemic CT is accepted as the cornerstone of PE-DLBCL treatment, but a general consensus regarding the therapeutic effect of rituximab in PE-DLBCL has not been reached. A single-center study retrospectively analyzed 48 PE-NHL patients and confirmed that combined rituximab therapy did not improve OS (P=0.361), likely influenced by the selection bias for patients whose primary sites were adrenal, ovarian or pancreatic; other commonly involved organs, including the GI tract, were excluded ([@b7-ol-0-0-8803]). However, other studies have demonstrated that rituximab may improve the OS and PFS of patients with DLBCL with primary GI tract, adrenal and breast involvement ([@b51-ol-0-0-8803]--[@b55-ol-0-0-8803]). The present study demonstrated that the addition of rituximab to CT significantly improved the OS and PFS rates of patients with PE-DLBCL. However, as it was a non-randomized comparison, future prospective studies are required to confirm this observation.

IPI and its variants are the main prognostic tools used in patients with DLBCL and, in the present study, the 3-year OS rates were 82.1, 61.2, 50.0 and 46.1% for patients in low, low-intermediate, high-intermediate and high-risk groups, respectively. The difference was statistically significant, and the multivariate analysis also indicated that IPI ≥2 was an independent risk factor for PE-DLBCL. Therefore, IPI was also suitable for assessing the prognosis of patients with PE-DLBCL (P=0.017).

Recent studies have demonstrated that patients with DLBCL may be divided into two groups of different prognoses using the Hans classification; in addition, the germinal center B-cell (GCB) type is associated with a better prognosis than the non-GCB type ([@b56-ol-0-0-8803],[@b57-ol-0-0-8803]). Furthermore, it has been reported that the majority of patients with primary breast, adrenal and CNS DLBCL are of the non-GCB type ([@b52-ol-0-0-8803],[@b58-ol-0-0-8803]--[@b63-ol-0-0-8803]). In the present study, a total 44/67 patients were non-GCB type, and primary CNS (14/17) and adrenal gland (5/5) accounted for the majority of these cases. The 3-year OS rate for GCB was not significantly higher than non-GCB, perhaps because the origin of the cells or the genetic causes of PE-DLBCL were different from those of primary intra-nodal DLBCL, as studies have demonstrated that PCNS-DLBCL is primarily non-GCB, but sequencing suggests that the cell source of original nodal non-GCB DLBCL and PCNS-DLBCL are different ([@b64-ol-0-0-8803]).

There are discrepancies in the prognosis of PE-DLBCL originating from different sites. Primary thyroid lymphoma (PTL) is associated with a relatively favorable prognosis ([@b32-ol-0-0-8803],[@b65-ol-0-0-8803],[@b66-ol-0-0-8803]), and in a study considering 108 cases of PTL, there was no mortality in the follow-up period for patients with stage I disease ([@b65-ol-0-0-8803]). The reason for this may be that \~90% of these patients were diagnosed at an early stage ([@b32-ol-0-0-8803],[@b65-ol-0-0-8803]). However, the prognosis for PA-DLBCL is relatively poor ([@b52-ol-0-0-8803],[@b67-ol-0-0-8803]), and the event-free survival for elderly patients with PA-DLBCL was only 12--18 months ([@b68-ol-0-0-8803],[@b69-ol-0-0-8803]). In the present study, the 3-year OS rates for PT-DLBCL and PA-DLBCL were 100 and 48.1%, respectively. However, since the number of PT-DLBCL cases was small, the difference was not statistically significant.

A number of centers have reported that involvement of the breast, renal, adrenal or female reproductive system is associated with a high risk of CNS recurrence ([@b7-ol-0-0-8803],[@b70-ol-0-0-8803]--[@b75-ol-0-0-8803]), but the mechanism of this remains unclear. L265P mutations of MYD88 are common in PCNS-DLBCLs (38--75%) ([@b45-ol-0-0-8803],[@b76-ol-0-0-8803],[@b77-ol-0-0-8803]), and these mutations were predominantly present in primary testicle and breast DLBCLs, whereas the mutation rate in PGI-DLBCL was relatively low ([@b76-ol-0-0-8803],[@b78-ol-0-0-8803]). These observations indicate that the mutation of MYD88 may be associated with the preferential dissemination to CNS. In the present study, PFGS-DLBCL and PA-DLBCL were risk factors, as determined by multivariate analysis; our previous study demonstrated that patients with PFGS-DLBCL have a high frequency of MYD88 mutations ([@b61-ol-0-0-8803]). However, we have not yet sequenced the specimens from patients with PA-DLBCL, and the reason patients with PA-DLBCLs are more likely to experience CNS relapse remains unclear. It is possible that PE-DLBCL involves organs with preferential dissemination to the CNS, representing a distinct cohort of DLBCL driven by equivalent oncogenic mutations. However, a large cohort study is required to confirm this hypothesis, and further molecular analysis may elucidate the specific nature of extra-nodal DLBCLs with preferential dissemination to CNS.

Patients with the recurrence of NHL in the CNS exhibit a poor prognosis, and solving this problem is urgent. Intrathecal MTX is used to prevent CNS relapse, but the present study revealed that it did not provide sufficient prevention (P=0.876), consistent with previous reports ([@b66-ol-0-0-8803],[@b79-ol-0-0-8803]). The reason for this may be that CNS recurrence is more frequent in the parenchyma than the meninges and thus, the typical intrathecal injection is less effective. A multicenter retrospective analysis revealed that the continuous intravenous infusion of HD-MTX (1--3 g/m^2^) over 24 h may reduce the likelihood of CNS recurrence ([@b80-ol-0-0-8803]). In the present study, the CNS RFS for patients who received HD-MTX (1 g/m^2^) was not significantly higher than that in untreated patients. This may be because there were too few cases for the data to reach significance, or because the concentration of MTX in the cerebrospinal fluid (CSF) may not have reached 0.5 mmol/l, which is the concentration required to kill tumor cells ([@b81-ol-0-0-8803]). Therefore, the detection of the concentration of MTX in the CSF requires further investigation.

The addition of rituximab has improved the outcomes in DLBCL, but there is no general consensus regarding the impact of rituximab in preventing CNS recurrence. Certain studies have indicated that rituximab may reduce CNS recurrence ([@b82-ol-0-0-8803]--[@b85-ol-0-0-8803]), while others have suggested that adding rituximab did not lower the incidence of CNS recurrence ([@b86-ol-0-0-8803],[@b87-ol-0-0-8803]). The present study demonstrated that CT combined with rituximab may effectively prevent CNS recurrence. Considering that only 1% of the rituximab dose can cross the blood-brain barrier, the present study revealed that it significantly improved the OS and PFS of patients with PE-DLBCL, indicating that rituximab may lower the risk of recurrent CNS by reducing the tumor burden.

In summary, the overall prognosis of patients with PE-DLBCL was analyzed, and it was revealed that CT, whether combined with surgery or RT, did not improve the prognosis of patients. Therefore, it is advisable that surgery is used for diagnosing and treating acute complications. However, the implications of the present study are limited by the number of patients; a study with a larger cohort is required. Preventing CNS relapse is urgent; and patients with primary FGS and adrenal gland involvement were identified as exhibiting an increased risk. Treatment with rituximab was demonstrated to be effective for CNS relapse prevention. Additionally, the intravenous infusion of HD-MTX lowered the rate of CNS relapse, although the effect was not statistically significant. Therefore, future studies with larger sample sizes are required to fully elucidate the efficacy of rituximab.
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![Overall survival for patients with PE-DLBCL or PT-DLBCL. (A) As demonstrated by the Kaplan-Meier curve, the 3-year overall survival rate for patients with PE-DLBCL was 64.1%. (B) Compared with the patients with PA-DLBCL, the patients with PT-DLBCL experienced an improved prognosis. However, this difference was not statistically significant (P=0.178). PE-DLBCL primary extra-nodal diffuse large B-cell lymphoma, PT-DLBCL primary thyroid diffuse large B cell lymphoma, PA-DLBCL, primary adrenal gland diffuse large B cell lymphoma.](ol-16-02-1602-g00){#f1-ol-0-0-8803}

![Identification of risk factors in PE-DLBCL. Univariate analysis demonstrated that (A) elevated LDH, (B) B symptoms, (C) Ann Arbor stage III--IV, (D) lack of treatment with rituximab, (E) CR not achieved following first-line treatment and (F) IPI \>2 were risk factors for PE-DLBCL. PE-DLBCL, primary extra-nodal diffuse large B-cell lymphoma; LDH, lactate dehydrogenase; CR, complete remission; IPI, International prognostic index.](ol-16-02-1602-g01){#f2-ol-0-0-8803}

![Overall survival for patients stratified by IPI score. The difference in survival rates for patients with IPI low risk, low-intermediate risk, high-intermediate risk and high risk was statistically significant (P=0.017). IPI, International prognostic index.](ol-16-02-1602-g02){#f3-ol-0-0-8803}

![Effect of rituximab and HD-MTX on survival rate. (A) Patients receiving the R-CHOP regimen exhibited a lower incidence of CNS recurrence than those receiving the CHOP regimen. (B) Intravenous infusion of HD-MTX combined with CHOP yielded no significant difference in the CNS recurrence rate compared with those who did not receive HD-MTX. HD-MTX, high-dose methotrexate; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vindesine, and prednisone; CNS, central nervous system; CHOP, cyclophosphamide, doxorubicin, vindesine and prednisone.](ol-16-02-1602-g03){#f4-ol-0-0-8803}

###### 

Patient characteristics according to the primary involved site.

  Characteristics                                                    GI tract      CNS           Breast       Adrenal gland   FGS          Thyroid gland   Bone
  ------------------------------------------------------------------ ------------- ------------- ------------ --------------- ------------ --------------- ------------
  Total                                                              42            38            19           15              12           8               7
  Age, years                                                                                                                                               
    Median                                                           56            58            53           62              59           61              56
    Range                                                            15--77        17--78        20--77       43--73          20--77       54--77          12--68
    Age \>60 years                                                   17            14            3            9               5            4               2
  Sex                                                                                                                                                      
    Male                                                             28            27            0            8               0            2               6
    Female                                                           14            11            19           7               12           6               1
    B symptoms                                                       24            4             2            7               3            0               5
    Increased serum lactate dehydrogenase                            18            13            3            10              4            4               3
    ECOG performance status \>1                                      13            22            1            7               0            4               3
  Ann Arbor stage                                                                                                                                          
    I + II                                                           25            34            10           3               6            8               1
    III + IV                                                         17            4             9            12              6            0               6
  Lugano stage                                                                                                                                             
    I--IIE                                                           33            --            --           --              --           --              --
    IV                                                               9             --            --           --              --           --              --
  International prognostic index                                                                                                                           
    Low                                                              12            8             11           0               6            3               2
    Low-intermediate                                                 8             14            4            4               1            1               2
    High-intermediate                                                11            5             4            2               5            1               2
    High                                                             11            11            0            9               0            3               1
    Bone marrow involvement                                          2             0             2            1               1            0               1
  Hans classification                                                                                                                                      
    GCB                                                              9             3             5            0               2            3               1
    Non-GCB                                                          11            14            6            5               3            2               3
  Treatment                                                                                                                                                
    Chemotherapy without rituximab                                   7             22            7            4               6            0               3
    Chemotherapy with rituximab                                      35            17            12           9               6            8               4
    Chemotherapy with surgery                                        23            5             5            0               8            4               0
  Risk of CNS relapse^[a](#tfn1-ol-0-0-8803){ref-type="table-fn"}^                                                                                         
    Low                                                              12            --            11           0               7            3               2
    Moderate                                                         18            --            8            4               0            2               3
    High                                                             12            --            0            11              5            3               2
  CNS prophylaxis                                                                                                                                          
    Intrathecal injection                                            19            --            1            5               3            4               4
    Intravenous injection of methotrexate                            8             --            5            5               0            0               1
    Combined prophylaxis                                             3             --            5            2               2            1               0
    Median follow-up time, months                                    36 (1--108)   29 (1--116)   22 (3--60)   14 (1--94)      13 (6--84)   24 (16--51)     16 (9--20)
    Loss to follow-up                                                0             7             5            0               1            0               3

Risk of CNS relapse was based on the National Comprehensive Cancer Network guidelines. GI, gastrointestinal; CNS, central nervous system; FGS, female genital system; ECOG, Eastern Cooperative Oncology Group; GCB, germinal center B-cell.

###### 

Distribution of primary extra-nodal diffuse large B-cell lymphoma cases.

  Extra-nodal sites          No. of patients
  -------------------------- -----------------
  Gastrointestinal tract     42
  Stomach                    20
  Colon                      8
  Ileocecum                  7
  Small intestine            7
  Central nervous system     38
  Deep brain tissue          34
  Multiple lesions           20
  Breast                     19
  Unilaterally involved      19
  Adrenal gland              15
  Bilaterally involved       8
  Female genital system      12
  Ovary                      6
  Cervix                     3
  Uterine body               3
  Both cervix and vagina     2
  Thyroid gland              8
  Bone                       7
  Axial skeleton             5
  Skull                      2
  Pelvis and spinal column   2
  Pelvis                     1
  Limbs                      2

###### 

Univariate and multivariate analysis of the survival of patients with primary extra-nodal diffuse large B-cell lymphoma.

                                      3-year overall survival   3-year progression-free survival                                                                                      
  ----------------------------------- ------------------------- ---------------------------------- --------- ---------------------- --------- ------ --------- ---------------------- ---------
  Sex                                                                                              0.899                                             0.853                            
    Male                              62                        62.8                                                                          64.1                                    
    Female                            63                        67.3                                                                          77.2   0.634                            
  Age                                                                                              0.799                                                                              
    ≤60 years                         75                        61.6                                                                          64.1                                    
    \>60 years                        50                        66.2                                                                          64.3                                    
  LDH                                                                                              0.001                                             0.084                            
    Normal                            74                        76.2                                                                          68.1                                    
    Elevated                          51                        45.6                                                                          57.9                                    
  B symptoms                                                                                       0.009                                             0.703                            
    No                                78                        78.4                                                                          69.5                                    
    Yes                               47                        49.5                                                                          59.4                                    
  ECOG performance status                                                                          0.096                                             0.536                            
    ≤1                                76                        72.4                                                                          65                                      
    \>1                               49                        56.4                                                                          63                                      
  Ann Arbor stage                                                                                  \<0.001                                           0.022                            
    I + II                            75                        85.8                                                                          75.6                                    
    III + IV                          50                        54.3                                                                          60                                      
  International prognostic index                                                                   0.023                                             0.901                            
    0--2                              66                        74.1                                         1.864 (1.002--3.468)   0.049     66.9                                    
    3--5                              59                        58                                                                            60                                      
  Rituximab                                                                                        \<0.001   0.259 (0.138--0.483)   \<0.001          \<0.001   0.297 (0.151--0.584)   \<0.001
    No                                41                        42.1                                                                          44.3                                    
    Yes                               83                        76.1                                                                          74.4                                    
  CR following first-line treatment                                                                \<0.001   0.134 (0.042--0.430)   0.001            0.001     0.417 (0.211--0.825)   0.012
    No                                51                        52.8                                                                          34.5                                    
    Yes                               73                        87.7                                                                          75.9                                    
  Pathology                                                                                        0.213                                             0.237                            
    Non-GCB                           26                        67                                                                            56.9                                    
    GCB                               32                        95.2                                                                          78.6                                    
  Bone marrow involvement                                                                          0.134                                             0.396                            
    No                                118                       64.8                                                                          65.4                                    
    Yes                               7                         41.7                                                                          41.7                                    
  Primary organ                                                                                    0.442                                             0.451                            
    Gastrointestinal tract            42                        62.6                                                                          77.1                                    
    Central nervous system            31                        60.4                                                                          57.4                                    
    Adrenal gland                     15                        48.1                                                                          48.4                                    
    Breast                            14                        61.9                                                                          50.3                                    
    Female genital system             11                        75                                                                            49.9                                    
    Thyroid                           8                         100                                                                           100                                     
    Bone                              4                         75                                                                            75                                      

HR, hazard ratio; CI, confidence interval; LDH, lactate dehydrogenase; ECOG, Eastern Cooperative Oncology Group; CR, complete remission; GCB, germinal center B-cell.

###### 

Survival analysis of patients with primary extra-nodal diffuse large B-cell lymphoma treated with chemotherapy combined with surgery.

                           3-year overall survival rate (%)   3-year progression free survival rate (%)                         
  ------------------------ ---------------------------------- ------------------------------------------- ------- ------ ------ -------
  Gastrointestinal tract   77.9                               68.4                                        0.622   90     100    0.254
  Female genital system    66.7                               87.5                                        0.592   66.7     50   0.955
  Breast                   53.3                               75                                          0.479   25       75   0.257

###### 

Univariate and multivariate analysis of risk factors for CNS relapse.

                                                    Univariate analysis   Multivariate analysis      
  -------------------------------- ---- ----------- --------------------- -------------------------- -------
  Sex                                               0.054                 1.549 (0.255--9.431)       0.635
    Male                           40   2 (4.9)                                                      
    Female                         54   9 (16.7)                                                     
  Age                                               0.980                                            
    ≤60 years                      56   7 (12.3)                                                     
    \>60 years                     38   4 (10.5)                                                     
  Lactate dehydrogenase                             0.354                                            
    Normal                         52   5 (9.4)                                                      
    Elevated                       42   6 (14.3)                                                     
  B symptoms                                        0.345                                            
    No                             54   8 (14.5)                                                     
    Yes                            40   3 (7.5)                                                      
  ECOG performance status                           0.506                                            
    0--1                           68   9 (13.2)                                                     
    \>1                            26   2 (7.0)                                                      
  International prognostic index                    0.202                                            
    0--2                           49   8 (16.3)                                                     
    3--5                           45   3 (6.7)                                                      
  Ann Arbor stage                                   0.321                                            
    I + II                         53   5 (9.4)                                                      
    III + IV                       41   6 (14.6)                                                     
  Treatment regimen                                 0.003                 0.160 (0.045--0.569)       0.005
    CHOP                           24   5 (20.8)                                                     
    R-CHOP                         70   6 (8.4)                                                      
  High-dose methotrexate                            0.689                                            
    No                             79   10                                                           
    Yes                            15   1                                                            
  Bone marrow involvement                           0.363                                            
    No                             87   11 (12.6)                                                    
    Yes                            7    0 (0.0)                                                      
  Risk of CNS relapse                               0.174                                            
    Low                            31   6 (19.4)                                                     
    Mediate                        31   1 (3.2)                                                      
    High                           32   4 (12.5)                                                     
  Intrathecal injection                             0.876                                            
    No                             63   8 (12.7)                                                     
    Yes                            31   3 (9.7)                                                      
  Primary organ                                                                                      
    Female genital system          11   6 (54.5)    \<0.001               14.839 (2.249--97.896)     0.005
    Adrenal gland                  15   3 (20.0)    0.101                 10.452 (1.737--62.908)     0.010
    Breast                         14   1 (7.1)     0.585                                            
    Bone                           4    1 (25.0)    0.288                                            
    Gastrointestinal tract         42   0 (0.0)     0.001                 0.000 (0--12.51×10^114^)   0.928
    Thyroid gland                  8    0 (0.0)     0.300                                            

CNS, central nervous system; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; CHOP, cyclophosphamide, doxorubicin, vindesine and prednisone; R-CHOP, rituximab, cyclophosphamide, doxorubicin, vindesine, and prednisone.
